No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Operating globally and domestically within China, Yunnan Baiyao Group Co., Ltd. specializes in the pharmaceutical industry. Its diverse portfolio encompasses health supplements, a wide array of medications, medical devices, traditional Chinese medicine ingredients, and even tea. These offerings are marketed under various brand identities, including Yunnan Baiyao, Yunfeng, Tong Qiaoqiao, Yunjian, Life, Jinkoujian, Langjian, Yangyuanqing, Caizhiji, Baiyao Health, Leopard Seven, Qiancaotang, Qiancao Meizi, and Tianzihong. The company, established in 1902, maintains its principal offices in Kunming, China.
www.yunnanbaiyao.com.cnNo one on the platform currently holds 000538.SZ.
No tracked institution reports a position in 000538.SZ as of their last filing.
No one on the platform has traded 000538.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 16.5% | 14.4% | 15.9% | — | — | — |
| Rev. Growth % | 2.9% | 4.7% | ||||
| Profit Margin % | 12.5% | 10.2% | 12.1% | |||
| Free Cash Flow Margin % | 10.0% | 9.4% | 8.6% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $42.4B | +0.6% | $3.11 | $3.04–$3.19 | — | 2 |
| 2027 | $43.8B | +3.3% | $3.34 | $3.29–$3.39 | — | 2 |
| 2028 | $45.2B | +3.2% | $3.58 | $3.52–$3.71 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 7 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-28 | $0.99 | $0.92 | -6.8% |
| 2026-04-30 | $0.92 | $1.14 | +23.6% |
| 2026-03-31 | $0.26 | $0.21 | -20.1% |
| 2025-10-31 | $0.73 | $0.66 | -10.2% |
| 2025-08-25 | $0.91 | $0.91 | +0.0% |
| 2025-04-25 | $1.05 | $1.08 | +2.9% |
| 2024-10-30 | $0.77 | $0.63 | -18.2% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 000538.SZYunnan Baiyao Group Co.,Ltd | $50.74 | -0.04% | $90.5B | — |
| 000423.SZDong-E-E-Jiao Co.,Ltd. | $46.11 | -0.77% | $29.5B | — |
| 000513.SZLivzon Pharmaceutical Group Inc. | $26.58 | -1.56% | $23.6B | — |
| 002737.SZSunflower Pharmaceutical Group Co.,Ltd | $11.31 | -1.14% | $6.6B | — |
| 002773.SZChengdu Kanghong Pharmaceutical Group Co., Ltd |
| $19.13 |
| -0.16% |
| $17.6B |
| — |
| 4524.TMorishita Jintan Co., Ltd. | $2246.00 | +0.36% | $9.2B | — |
| 600276.SSJiangsu Hengrui Medicine Co., Ltd. | $43.13 | -0.05% | $275.1B | — |
Source: Financial Modeling Prep · peers by sector/industry